CHO Cells News and Research

RSS

Researchers identify several gene mutations responsible for medulloblastoma

Researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital have identified several gene mutations responsible for the most common childhood brain tumor, called medulloblastoma, adding evidence to the theory that the diagnosis is a group of genetically distinct cancers with different prognoses. These and accompanying findings are likely to lead to less-toxic, better-targeted treatment approaches over the next two years, the researchers said.

23 Jul 2012

Yeast gene can increase ethanol production yield by up to 34%

iDiverse announced that it has discovered a yeast gene that when inserted into yeast and properly modulated can increase ethanol production yield by up to 34%.

23 Jul 2012

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

23 Jul 2012

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Two studies published in a recent issue of Cell Medicine report on the therapeutic efficacy of stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).

20 Jul 2012

Asian-American victims of domestic violence rarely seek help from police or health care providers

Asian-American victims of domestic violence rarely seek help from police or health care providers - "an alarming trend" among the fastest-growing racial group in the United States, says a Michigan State University researcher.

17 Jul 2012

Inspiration receives FDA clinical hold order for IB1001 phase III studies on hemophilia B

Ipsen announced today that its partner Inspiration Biopharmaceuticals Inc. (Inspiration) was notified by the Food and Drug Administration (FDA) that both clinical trials evaluating the safety and efficacy of IB1001, an investigational intravenous recombinant factor IX (rFIX) therapy for the treatment and prevention of bleeding episodes in people with hemophilia B, were placed on clinical hold.

10 Jul 2012

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.

18 Jun 2012

Research roundup: Best health care for homeless, new business model for pharma

The cost and coordination of health care for homeless individuals can be a challenge for states. But as this brief describes, establishing supportive housing - which provides social services, usually on site - "can help improve health, increase survival rates, foster mental health recovery, and reduce alcohol and drug use."

16 Jun 2012

Seniors increasingly cared for in multi-generational homes

NPR examines how families are living under the same roof to care for senior relatives -- and also, to get by.

30 May 2012

Treatment of OSA in children can reverse neuronal brain injury

Treatment of obstructive sleep apnea (OSA) in children normalizes disturbances in the neuronal network responsible for attention and executive function, according to a new study.

21 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

SK Biopharmaceuticals receives FDA Orphan Drug status for carisbamate

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it was granted special status by the U.S. Food and Drug Administration (FDA) for carisbamate for the management of patients with infantile spasms (IS), a form of epilepsy associated with increased risk of death or mental retardation.

20 Apr 2012

Positive results from CrystalGenomics’ CG100649 Phase 2b OA study

CrystalGenomics, Inc., a biopharmaceutical company headquartered in Korea, has just announced positive results from the Phase 2b osteoarthritis (OA) study of the CG100649, CrystalGenomics' next-generation NSAID candidate.

19 Apr 2012

Powerful link between circadian rhythms and metabolism

The discovery of a major gear in the biological clock that tells the body when to sleep and metabolize food may lead to new drugs to treat sleep problems and metabolic disorders, including diabetes.

7 Apr 2012

New method uses E. coli bacteria to engineer human therapeutic glycoproteins

Escherichia coli - a bacteria considered the food safety bane of restaurateurs, grocers and consumers - is a friend. Cornell University biomolecular engineers have learned to use E. coli to produce sugar-modified proteins for making pharmaceuticals cheaper and faster.

27 Mar 2012

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811.

17 Mar 2012

Thermo Fisher launches HyCell CHO medium

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific HyCell CHO cell-culture medium, a versatile animal-derived- component-free (ADCF) and chemically defined (CD) medium for culturing a broad variety of CHO cells.

From Thermo Fisher Scientific Inc. 17 Mar 2012

SK Biopharmaceuticals' YKP3089 receives Korea Drug Development Fund

South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years.

3 Mar 2012

Scientist uses GPUs to simulate inner workings of human cells

The cure for cancer comes down to this: video games. In a research lab at Wake Forest University, biophysicist and computer scientist Samuel Cho uses graphics processing units (GPUs), the technology that makes videogame images so realistic, to simulate the inner workings of human cells.

17 Feb 2012

CrystalGenomics raises KRW 3 billion in private placement

CrystalGenomics, Inc., a clinical stage biopharmaceutical company headquartered in Korea, has just announced that it has successfully raised KRW 3 Billion (USD 2.6 Million) in a private placement to the Korea Seoul Life Science Fund.

13 Jan 2012